1st prize of the Innovationsnetzwerk Niedersachsen 2017 was awarded to Yumab and the TU Braunschweig at the Hannover Messe by the Minister for Science and Culture, Gabriele Heinen-Kljaji, and the Minister for Economics, Employment and Traffic, Olaf Lies
Meet YUMAB CEO Thomas Schirrmann at the J.P. Morgan 35th Annual Healthcare Conference 2017 San Francisco (January 9-12, 2017).
YUMAB cofounder Michael Hust will present YUMAB technologies at Toxins 2017 in Madrid (January 18-21, 2017).
Meet André Frenzel, YUMAB CSO and cofounder, and Michael Hust, YUMAB cofounder, at Antibodies in Drug Discovery in Cambridge, UK (March 6+7, 2017).
Meet YUMAB head of development Dr. Jonas Kügler at the „Antibody Engineering & Therapeutics“ in San Diego December 11th to 15th at the booth of the Antibody Society.
YUMAB cofounder Michael Hust will present current antibody developments against pathogens and YUMAB technologies at Vaccines 2016 in Cartagena (November 10th-12th 2016).
Meet YUMAB cofounder and CEO Thomas Schirrmann at Bio-Europe in Cologne (November 7th to 9th).
YUMAB cofounder Stefan Dübel will present YUMAB Technologies and Antibody Developments at PEGS Europe (October 31th to November 4th 2016).
YUMAB cofounder Michael Hust will present YUMAB Technologies and Antibody Developments at „Discovery on Target“ in Boston (September 19th-22th)
YUMAB Cofounder Michael Hust will give a course on antibody engineering at the „Next-Generation Antibody Therapeutics“ training event in Hamburg (Mai 12/13, 2016)
YUMAB cofounders Stefan Dübel and Michael Hust will present YUMAB Technologies and Antibody Developments at PEGS Boston (April 25-29, 2016)
Meet Yumab-Cofounder Stefan Dübel in New York at at the World Technology Summit (Nov 19-20) where he speaks on Yumab technology and has been selected as finalist for the World Technology Award 2015
YUMAB cofounder Stefan Dübel received the „2015 Innovation in Biotechnology Award“ of the American Association of Pharmaceutical Scientists (AAPS) at the 2015 AAPS National Biotechnology Conference in San Francisco
YUMAB and Merck KGaA successfully generated improved human antibody gene libraries for the development of therapeutic antibodies
YUMAB receives sponsorship from the European Regional Development Fund in the context of the „Europa fördert Niedersachsen“ program (ZW3-80141465)